Intrommune Therapeutics
Early Stage
Intrommune Therapeutics is a New York City-based biopharmaceutical company developing a new, simple treatment for food allergies.
Overview
Raised: $157,806
Total Commitments ($USD)
Platform
Netcapital
Start Date
04/13/2018
Close Date
06/29/2018
Min. Goal
$10,000
Max. Goal
$1,069,950
Min. Investment
$99
Security Type
Equity - Common
SEC Filing Type
RegCF
/ RegD 506(c)
Price Per Share
$1.00
Pre-Money Valuation
$15,000,000
Rolling Commitments ($USD)
Status
Funded
Reporting Date
07/08/2018
Days Remaining
Funded
% of Min. Goal
1,578%
% of Max. Goal
15%
Likelihood of Max
Funded
Avg. Daily Raise
$2,049
Momentum
Funded
Create a free account today to gain access to KingsCrowd analytics.
Year Founded
2013
Industry
Healthcare & Pharmaceuticals
Tech Sector
HealthTech
Location
New York, New York
What if treating your allergies was as easy as….brushing your teeth? Well, with Intrommune Therapeutics, it now just might be! This New York City-based biopharmaceutical company is developing a toothpaste that uses oral mucosal immunotherapy (OMIT) to help people with peanut allergies overcome them. OMIT is based on allergy immunotherapy, which adheres to the idea that if patients receive tiny, carefully controlled amounts of the substance they are allergic to, their immune system learns that the substance is safe, and their allergic reactions become milder. Intrommune’s great-tasting, cavity-fighting toothpaste exposes patients to a low, safe dose of a peanut-derived protein in the toothpaste, with the goal of desensitizing the immune system’s reaction. They are developing this toothpaste in accordance to FDA guidelines, and there is no current FDA-approved treatment for any peanut for food allergy.
Create a free account today to gain access to KingsCrowd analytics.
Raise History
| Offering Name | Close Date | Platform | Valuation/Cap | Total Raised | Security Type | Status | Reg Type |
|---|---|---|---|---|---|---|---|
| Intrommune Therapeutics | 07/07/2021 | Self Managed | - | $0 | Equity - Common | Funded | RegD 506(c) |
| Intrommune Therapeutics | 06/29/2018 | Netcapital | $15,000,000 | $157,806 | Equity - Common | Funded | RegCF / RegD 506(c) |
Create a free account today to gain access to KingsCrowd analytics.
Upgrade to gain access
Pay Monthly
Annually (Save 17%)
-
$12.42 /month
billed annually - Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings (excluding risk)
- Advanced company search ( with ratings)
- Markets page filters and historical industry data
- Get Edge Annual
Edge
-
$41.58 /month
billed annually - Full site access including KingsCrowd's qualitative analyst reports.
- Plan Includes:
- Everything in Edge, plus
- Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
- Search and filter based on Analyst Reports
- In-depth risk ratings for every raise
- Get Edge Pro Annual
Edge Pro
Already a member? Log in here.
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.